Medical congresses present an important opportunity for the science and medical community to come together and participate in the open exchange and dialogue around the latest science for a particular therapeutic area (TA). The 2014 American Heart Association Scientific Sessions (AHA ‘14) are no different.
Taking place this year in Chicago, IL from November 15–19, AHA is recognized as the leading cardiovascular (CV) congress in the US with a strong global presence, attracting attendees from more than 100 countries.
For companies like AstraZeneca, attending and having a leadership presence at AHA ‘14 is fundamental to our business as it helps us better understand our customers, the market and evolving science in CV and metabolic disease (CVMD). As a company that leads the way in the clinical research of lipid and platelet biology, AHA ‘14 also gives us the chance to participate in the scientific discussions around these key areas that add to the body of evidence in cardiovascular disease (CVD). As research presented at AHA tends to demonstrate, there is still a tremendous unmet need in the management of at-risk patients with risk factors for CVD, and AstraZeneca remains committed to these patients to ensure they are informed about our broad portfolio of CVMD medicines.
Worldwide, more than 17 million patients suffer or die from CVMD each year; therefore it’s important that we continue to follow the science around these intertwined diseases in the interest of the patients we ultimately serve.
“AstraZeneca has a long-standing commitment to improving patient health through scientific excellence in CVMD,” said Paul Spittle, Vice President, Cardiovascular & Respiratory, AstraZeneca. “With a 100-year legacy in this space, our singular CVMD presence at AHA ‘14 will tell a unified story around the science and innovation behind our medicines in this key therapy area.”
The AstraZeneca booth at this year’s meeting offers healthcare professionals an opportunity to interact with the latest information about our medicines and ongoing clinical research. Each section of the booth will incorporate innovative technology to tell a compelling clinical story.
Building on the themes of technology and innovation, AstraZeneca has developed the official meeting iPad application (app), Conference Notes, a novel tool that promotes scientific exchange and will help delegates get the most out of medical conferences. This iPad app allows attendees to plan their schedules in advance, bookmark and take notes on key slides and store presentations for future reference.
Paul Spittle, Vice President, Cardiovascular & Respiratory, AstraZeneca